Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.62 |
| ▸ | BACE1 | P56817 | 4/20 | 0.62 |
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18587402 | 0.98 | ACHE (0.61) | ACHEBACE1BCHECHEK1MEN1 | |
| Water SCHEMBL22683358 | 0.98 | ACHE (0.61) | ACHEBACE1BCHECHEK1MEN1 | |
| SCHEMBL20794626 | 0.94 | BCHE (0.57) | ACHEBACE1BCHECHEK1MEN1 | |
| SCHEMBL20794625 | 0.94 | BCHE (0.57) | ACHEBACE1BCHECHEK1MEN1 | |
| Piperazine SCHEMBL28117207 | 0.93 | ACHE (0.56) | ACHEBACE1BCHECHEK1MEN1 | |
| Oxalic Acid SCHEMBL28548418 | 0.91 | BCHE (0.58) | ACHEBACE1BCHECHEK1MEN1 | |
| SCHEMBL20794851 | 0.90 | BCHE (0.60) | ACHEBACE1BCHECHEK1MEN1 | |
| SCHEMBL13573579 | 0.85 | GRIN2B (0.50) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL4202912 | 0.85 | ACHE (0.64) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL21235736 | 0.85 | CARM1 (0.50) | ACHEBACE1BCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215081-B2 | Pharmaceutical intermediate | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2025-02-04 | — | — | US | claimed |
| CN-115010651-B | Fixed bed synthesis method of N- (4-fluorobenzylamino) -1-methylpiperidine | 合肥立方制药股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-111303013-B | Preparation method of pimavanserin | 福建省微生物研究所 | 2023-10-13 | — | — | CN | claimed |
| CN-115677566-A | Preparation method of pimavanserin | 华中药业股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-20220213037-A1 | A PHARMACEUTICAL INTERMEDIATE | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2022-07-07 | — | — | US | claimed |
| CN-114280175-A | Method for detecting impurities in pimavanserin starting material by UHPLC (ultra high performance liquid chromatography) | 丽珠集团新北江制药股份有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-110156664-B | Method for synthesizing pimavanserin | 常州大学 | 2022-03-01 | — | — | CN | claimed |
| EP-3741744-B1 | A PHARMACEUTICAL INTERMEDIATE FOR PREPARING PIMAVANSERIN | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2022-01-05 | — | — | EP | claimed |
| CN-113336695-A | Preparation method and application of 4- (4-fluorobenzylamino) -1-methylpiperidine | 苏州铭开生物医药技术有限公司 | 2021-09-03 | — | — | CN | claimed |
| EP-3828170-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | Livzon New North River Pharmaceutical Co., Ltd. (CN) | 2021-06-02 | — | — | EP | claimed |
| EP-2289879-B1 | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt | ACADIA PHARM INC (US) | 2014-11-12 | — | — | EP | claimed |
| US-7790899-B2 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | claimed |
| CN-101778821-A | Synthesizing of N-(4-luorobenzyl)-N-(1-methyl piperidine-4-yl)-N '-(4-(2-methyl propoxy-) phenyl methyl) urea and tartrate and crystal formation | ACADIA PHARM INC | 2010-07-14 | — | — | CN | claimed |
| EP-2146960-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008144326-A2 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(L-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | claimed |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. | 2007-11-08 | — | — | US | claimed |
| CN-101035759-A | Synthesis and crystalline forms of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N' - (4- (2-methylpropyloxy) phenylmethyl) urea and its tartrate salt | ACADIA PHARM INC (US) | 2007-09-12 | — | — | CN | claimed |
| EP-1794126-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | Acadia Pharmaceuticals Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. | 2006-05-18 | — | — | US | claimed |
| WO-2006037043-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | ACADIA PHARMACEUTICALS INC. (US) | 2006-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213037-A1 | A PHARMACEUTICAL INTERMEDIATE | PIM1, PAH, PIM3 | ACHE 851/4885BACE1 2974/4885BCHE 617/4885 |
| US-12215081-B2 | Pharmaceutical intermediate | PIM1, PAH, PIM3 | ACHE 842/4885BACE1 2934/4885BCHE 589/4885 |
| US-20070260064-A1 | SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS | MTAP, CPN1, DNPEP | ACHE 852/4885BACE1 3595/4885BCHE 1664/4885 |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | MTAP, CPN1, DNPEP | ACHE 726/4885BACE1 3452/4885BCHE 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.